StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)

Close on Nov 20, 2026

Genmab A/S Phase 2 Sponsored Interventional Studies by Quarter

Genmab A/S Phase 2 Sponsored Interventional Studies: 68 in Q3 2026, up 7.9% from a year earlier. That is the highest of the 43 quarters on record here.

Latest, Q3 2026
68
Period ended Sep 30, 2026
Change on a year earlier
+7.9%
63 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
1
NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies

Where the Q3 2026 figure comes from

Source: NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPhase 2 Sponsored Interventional StudiesYear on yearSource
Q3 2026Sep 30, 202668+7.9%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2026Jun 30, 202666+8.2%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2026Mar 31, 202665+12.1%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2025Dec 31, 202564+16.4%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2025Sep 30, 202563+16.7%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2025Jun 30, 202561+22.0%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2025Mar 31, 202558+20.8%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2024Dec 31, 202455+14.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2024Sep 30, 202454+14.9%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2024Jun 30, 202450+11.1%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2024Mar 31, 202448+11.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2023Dec 31, 202348+17.1%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2023Sep 30, 202347+20.5%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2023Jun 30, 202345+21.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2023Mar 31, 202343+19.4%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2022Dec 31, 202241+24.2%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗

Cite this data

StockData. (2026). Genmab A/S Phase 2 Sponsored Interventional Studies, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/ctgov-phase2-studies

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?